Clinical Trial Update: Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial of trilaciclib in combination with docetaxel for second-line and beyond locally advanced or metastatic non-small cell lung cancer; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cosela (trilaciclib) (trilaciclib)
• Taxotere (docetaxel) (docetaxel)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Non-Small Cell Lung Cancer, Myelosuppression | Phase 2 | Status: RECRUITING